Floatz logo

Capivasertib

Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia

Princess Maxima Center for Pediatric OncologySmall moleculePhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Refractory Precursor T-Lymphoblastic Lymphoma/Leukemia cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Princess Maxima Center for Pediatric Oncology
Phase 1/2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 1/2CCC
PEGASPARGASE
M.D. Anderson Cancer Center
Phase 1/2CCC
Cpx-351
Children's Oncology Group
Phase 1/2CCC
PREDNISONE TABLETS
M.D. Anderson Cancer Center
Phase 1/2CCC

View all 34 →

Same molecule, other indications

Capivasertib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Advanced Non-small-cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →